Roots Analysis has been doing an in depth study Neoantigen Targeted Therapies, 2019-2030, covering key facets of the industry’s evolution and identifying potential future growth possibilities.

To buy this 320  page report, featuring 110  figures and 140  tables, check out here

Key Market Insights

•           Presently, over 150 neoantigen targeted therapies are now being evaluated for advanced cancer indications and are equipped for delivery via different routes of administration

•           Several molecules are in the beginning of clinical development according to delivery strategies, number of vaccines and immunotherapies have been in existence for targeting personalized and shared antigens

•           Over time, greater than 6,000 patents associated with neoantigens and affiliated therapies happen to be granted / filed this really is suggestive of the increased pace of research in this subject

•           Both industry and academic players are adding towards the innovation, that is apparent across printed scientific literature centered on multiple targeted therapies for an array of cancer indications

•           Several investors, getting recognized the untapped chance in this particular emerging segment of cancer immunotherapy, have invested over USD 7 billion across 150 instances at that time between 2014 and 2019

•           The growing traction in this subject can also be reflected within the partnership activity deals inked recently centered on an assorted selection of therapies, involving both worldwide and indigenous stakeholders

•           The market will get the needed impetus after approval from the first neoantigen targeted therapy the long run growth will probably be driven through the effective clinical connection between the late-stage molecules

•           In fact, opinions from skillfully developed read the vast potential of the segment of cancer immunotherapy, able to targeting personalized / off-the-shelf tumor antigens with multiple kinds of vaccines and therapies